Xcelerate Inc. (XCRT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Xcelerate Inc. (XCRT) trades at $0.01. Xcelerate Inc. focuses on acquiring and developing early-stage medical technologies for clinical settings. The company provides end-to-end medical technology development, aiming to accelerate innovation in healthcare. Market cap: $4.34M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for XCRT: XCRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XCRT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
XCRT: 1/1 perspectives are bearish.
How is this calculated? →Xcelerate Inc. (XCRT) Healthcare & Pipeline Overview
Xcelerate Inc. operates within the medical care facilities sector, acquiring and developing early-stage medical technologies. The company provides end-to-end development services for controlled clinical environments, focusing on trialing, testing, and applying innovative medical solutions. With a small market capitalization, Xcelerate navigates a competitive landscape.
What Is the Investment Thesis for XCRT?
Xcelerate Inc. presents a high-risk, high-reward investment profile due to its focus on early-stage medical technologies. The company's negative P/E ratio of -20.90 and a negative profit margin of -22.8% indicate current financial challenges. A potential growth catalyst lies in the successful development and commercialization of acquired technologies. However, the company's small market capitalization of $4.34M and limited number of employees (12) suggest significant operational and financial constraints. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainties inherent in early-stage technology development.
Based on FMP financials and quantitative analysis
XCRT Key Highlights
- Market capitalization of $4.34M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -20.90 reflects current losses and the need for successful commercialization of technologies.
- Gross margin of 25.1% suggests potential for profitability if revenue scales effectively.
- Beta of 0.72 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
- Profit margin of -22.8% highlights the company's current struggle to achieve profitability and the importance of cost management.
Who Are XCRT's Competitors?
XCRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBRRF Blueberries Medical Corp. | $0.01 | +0.00% | $5.30M | 59 |
| BICX BioCorRx Inc. | $0.40 | +17.65% | $8.35M | 52 |
| GBCS Selectis Health, Inc. | $5.21 | +0.00% | $15.98M | 49 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XCRT's Key Strengths?
- Focus on early-stage medical technology development.
- End-to-end service offering.
- Access to controlled clinical settings.
- Proprietary technology and patents.
What Are XCRT's Weaknesses?
- Small market capitalization.
- Negative profitability metrics.
- Limited number of employees.
- Reliance on successful technology development and commercialization.
What Could Drive XCRT Stock Higher?
- Successful completion of clinical trials for key technologies.
- Securing strategic partnerships with major hospital networks.
- Expansion of the company's patent portfolio.
- Increased adoption of Xcelerate's technologies in clinical settings.
What Are the Key Risks for XCRT?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from larger, more established companies.
- Financial constraints and funding challenges.
- Technological obsolescence and the need for continuous innovation.
What Are the Growth Opportunities for XCRT?
- Expansion into Telemedicine: The telemedicine market is projected to reach $460 billion by 2030, presenting a significant opportunity for Xcelerate to integrate its technologies into remote patient monitoring and virtual care solutions. This expansion would require strategic partnerships and adaptation of existing technologies for remote applications, potentially increasing revenue streams within the next 3-5 years.
- Strategic Partnerships with Hospitals: Collaborating with hospital networks to implement and test Xcelerate's technologies in real-world clinical settings can accelerate adoption and validation. Securing long-term contracts with hospitals can provide a stable revenue base and enhance the company's credibility. This initiative could yield substantial results within 2-3 years.
- Development of AI-Driven Diagnostics: Integrating artificial intelligence into diagnostic tools can improve accuracy and efficiency in clinical settings. The AI in healthcare market is expected to reach $95 billion by 2030. Xcelerate can leverage its existing technologies to develop AI-powered solutions, potentially attracting investment and increasing market share within 3-5 years.
- Focus on Geriatric Care Technologies: With the aging global population, there is a growing demand for technologies that improve geriatric care. Xcelerate can develop and market solutions tailored to the needs of elderly patients, such as remote monitoring devices and assistive technologies. This targeted approach can drive revenue growth within 2-4 years.
- Acquisition of Complementary Technologies: Acquiring companies with complementary technologies can expand Xcelerate's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and expertise, accelerating growth and enhancing the company's competitive position. This inorganic growth strategy could yield significant benefits within 1-3 years.
What Opportunities Does XCRT Have?
- Expansion into telemedicine and remote patient monitoring.
- Strategic partnerships with hospitals and medical facilities.
- Development of AI-driven diagnostic tools.
- Focus on geriatric care technologies.
What Threats Does XCRT Face?
- Regulatory hurdles and approval processes.
- Competition from larger, more established companies.
- Technological obsolescence.
- Financial constraints and funding challenges.
What Are XCRT's Competitive Advantages?
- Proprietary Technology: Ownership of unique engineering designs and patents.
- End-to-End Development: Comprehensive service offering from concept to clinical application.
- Controlled Clinical Settings: Access to environments for testing and validation.
- Specialized Expertise: Focus on early-stage medical technology development.
What Does XCRT Do?
Xcelerate Inc., formerly known as Union Dental Holdings, Inc., was incorporated in 1996 and is based in Coral Springs, Florida. The company specializes in acquiring engineering designs and patents, which are then applied to early-stage medical technology companies. Xcelerate's core business model revolves around supplying these technologies to controlled clinical care settings, where they can be trialed, tested, and ultimately implemented. This end-to-end approach allows for a comprehensive and controlled development process, from initial concept to practical application. Xcelerate positions itself as a facilitator of medical technology advancement, focusing on bridging the gap between innovative ideas and real-world clinical use. While the company's headquarters are in Coral Springs, its original incorporation was in Mauldin, South Carolina, reflecting its historical evolution.
What Products and Services Does XCRT Offer?
- Acquires engineering designs and patents.
- Applies acquired technologies to early-stage medical companies.
- Supplies technologies to controlled clinical care settings.
- Facilitates trials and testing of new medical technologies.
- Provides end-to-end medical technology development services.
- Focuses on bridging the gap between innovation and clinical application.
How Does XCRT Make Money?
- Acquire promising engineering designs and patents.
- Develop and refine these technologies for clinical applications.
- Supply developed technologies to controlled clinical settings for testing and implementation.
- Generate revenue through licensing agreements and technology sales.
What Industry Does XCRT Operate In?
Xcelerate Inc. operates within the medical care facilities industry, which is characterized by rapid technological advancements and increasing demand for innovative healthcare solutions. The industry is highly competitive, with companies ranging from established medical device manufacturers to smaller, specialized technology developers. Xcelerate's focus on early-stage technologies positions it within a niche segment of the market, requiring effective navigation of regulatory hurdles and successful commercialization of its acquired assets. The company's success depends on its ability to identify and develop promising technologies that address unmet needs in clinical care settings.
Who Are XCRT's Key Customers?
- Early-stage medical technology companies.
- Controlled clinical care settings.
- Hospitals and medical facilities.
- Healthcare providers seeking innovative solutions.
Xcelerate Inc. Financial Trajectory
Xcelerate Inc. (XCRT) reported $0 in revenue for Q1 2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $16K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, XCRT averaged $-0.00 in diluted EPS.
Company Profile
Xcelerate Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Coral Springs, US. The company is led by CEO Michael F. O'Shea. XCRT has traded publicly since 2001.
How Xcelerate Inc. Is Valued
Xcelerate Inc. carries a market capitalization of $4.34M, placing it in the micro-cap category.
ROE 70%Key Financial Metrics
Return on equity for Xcelerate Inc. stands at 70.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -23.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Xcelerate Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
XCRT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on early-stage medical technology development.
- End-to-end service offering.
- Access to controlled clinical settings.
- Proprietary technology and patents.
Bear Case
- Small market capitalization.
- Negative profitability metrics.
- Limited number of employees.
- Reliance on successful technology development and commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0 | -$15,630 | -$0.0000 |
| Q4 2025 | -$2M | -$883,270 | -$0.0020 |
| Q3 2025 | $531,921 | -$65,347 | -$0.0002 |
| Q2 2025 | $535,423 | -$161,880 | -$0.0004 |
Based on FMP financials and quantitative analysis
XCRT Latest News
No recent news available for XCRT.
XCRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XCRT.
Price Targets
Wall Street price target analysis for XCRT.
XCRT MoonshotScore
What does this score mean?
The MoonshotScore rates XCRT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael F. O'Shea
CEO
Michael F. O'Shea serves as the CEO of Xcelerate Inc., overseeing the company's strategic direction and operations. His background includes experience in managing and developing early-stage companies, with a focus on technology and healthcare sectors. O'Shea's expertise lies in identifying and nurturing innovative technologies, guiding them through the development process, and bringing them to market. He is responsible for leading a team of 12 employees and driving the company's growth initiatives.
Track Record: Under Michael F. O'Shea's leadership, Xcelerate Inc. has focused on acquiring and developing a portfolio of early-stage medical technologies. Key milestones include securing patents for innovative designs and establishing partnerships with clinical care settings for testing and validation. O'Shea has been instrumental in steering the company's strategic shift towards end-to-end medical technology development, positioning Xcelerate as a facilitator of healthcare innovation.
XCRT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Xcelerate Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risk due to the potential for limited information and price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Information Scarcity: Lack of comprehensive financial disclosures and regulatory oversight.
- Price Volatility: Higher price fluctuations due to limited trading activity.
- Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial challenges.
- Verify the company's legal standing and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Focus on medical technology development.
- Patents and intellectual property.
- CEO with relevant industry experience.
- End-to-end service offering.
- Partnerships with clinical care settings.
Xcelerate Inc. Healthcare Stock: Key Questions Answered
What does Xcelerate Inc. do?
Xcelerate Inc. operates as a facilitator of medical technology advancement, focusing on acquiring and developing early-stage technologies for clinical applications. The company supplies these technologies to controlled clinical care settings, where they are trialed, tested, and implemented. Xcelerate's end-to-end approach encompasses the entire development process, from initial concept to practical use, aiming to bridge the gap between innovation and real-world healthcare solutions. This model allows for a comprehensive and controlled environment for technology validation and adoption.
What do analysts say about XCRT stock?
Currently, there is no available analyst coverage or consensus on Xcelerate Inc. (XCRT) stock. Given the company's small market capitalization of $4.34M and OTC listing, it is not widely followed by major research firms. Investors should conduct their own due diligence and consider the company's financial metrics, growth potential, and risk factors before making any investment decisions. The absence of analyst coverage highlights the speculative nature of this investment.
What are the main risks for XCRT?
Xcelerate Inc. faces several key risks, including its small market capitalization, negative profitability metrics, and reliance on successful technology development. As an OTC-traded company, XCRT is subject to limited liquidity, information scarcity, and price volatility. Regulatory hurdles and competition from larger companies also pose significant challenges. Investors should carefully consider these risks and the uncertainties inherent in early-stage technology development before investing in Xcelerate Inc.
How does Xcelerate Inc. navigate regulatory approval processes?
As a developer of early-stage medical technologies, Xcelerate Inc. faces the challenge of navigating complex regulatory approval processes, primarily with the FDA in the United States. The company's strategy involves rigorous testing and validation of its technologies in controlled clinical settings to gather the necessary data for regulatory submissions. Xcelerate also collaborates with regulatory consultants to ensure compliance with applicable standards and guidelines. Successful navigation of these processes is critical for the commercialization of its technologies and future growth.
How does Xcelerate Inc. plan to achieve profitability?
Xcelerate Inc.'s path to profitability hinges on the successful commercialization of its acquired and developed medical technologies. The company aims to generate revenue through licensing agreements, technology sales, and strategic partnerships with hospitals and medical facilities. Cost management and operational efficiency are also crucial for improving profitability. Xcelerate's ability to scale its operations, secure funding for further development, and effectively market its technologies will determine its success in achieving sustainable profitability.
What are the key factors to evaluate for XCRT?
Evaluate XCRT on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does XCRT data refresh on this page?
XCRT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven XCRT's recent stock price performance?
Xcelerate Inc. (XCRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on early-stage medical technology development. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-traded companies.
- Financial data may not be fully up-to-date.